LEISHMANIASIS DRUG

Article

AEterna Laboratories reported recently the results of a phase III trial evaluating its drug Impavido (miltefosine) for the treatment of cutaneous leishmaniasis, showing that patients taking Impavido had a 220-percent better cure rate compared with those in a placebo group.

Related Videos
Related Content
© 2023 MJH Life Sciences

All rights reserved.